Ajovy
Total Payments
$3.6M
Transactions
1,065
Doctors
47
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $610.08 | 36 | 28 |
| 2022 | $20.98 | 1 | 1 |
| 2021 | $6,461 | 14 | 3 |
| 2019 | $2.4M | 770 | 14 |
| 2018 | $1.1M | 244 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 1,014 | 99.8% |
| Space rental or facility fees (teaching hospital only) | $6,250 | 3 | 0.2% |
| Food and Beverage | $789.77 | 47 | 0.0% |
| Education | $52.02 | 1 | 0.0% |
Payments by Type
Research
$3.6M
1,014 transactions
General
$7,092
51 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) | Teva Pharmaceuticals USA, Inc. | $534,411 | 2 |
| A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments | Teva Pharmaceuticals USA, Inc. | $495,735 | 1 |
| A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments | Teva Pharmaceuticals USA, Inc. | $371,881 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | Teva Pharmaceuticals USA, Inc. | $349,652 | 9 |
| A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double Blind, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of Persistent Posttraumatic Headache (PPTH) | Teva Pharmaceuticals USA, Inc. | $342,991 | 1 |
| A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double Blind, Placebo Controlled, Parallel Group Study, Including an Open-Label Period, Evaluating the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab for the Treatment of Posttraumatic Headache (PTH) | Teva Pharmaceuticals USA, Inc. | $312,965 | 1 |
| Clinical characteristics, healthcare utilization and outcomes of patients with migraine | Teva Pharmaceuticals USA, Inc. | $302,883 | 0 |
| A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Epidosic Cluster Headache | Teva Pharmaceuticals USA, Inc. | $257,895 | 1 |
| A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients | Teva Pharmaceuticals USA, Inc. | $204,554 | 0 |
| Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine | Teva Pharmaceuticals USA, Inc. | $180,738 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) Versus Placebo for the Preventive Treatment of Chronic Migraine | Teva Pharmaceuticals USA, Inc. | $85,669 | 1 |
| TV48125-CNS-10141 | Teva Pharmaceuticals USA, Inc. | $74,675 | 0 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder | Teva Pharmaceuticals USA, Inc. | $45,500 | 0 |
| A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine | Teva Pharmaceuticals USA, Inc. | $19,732 | 0 |
| TV48125-BE-10114 | Teva Pharmaceuticals USA, Inc. | $213.75 | 0 |
Top Doctors Receiving Payments for Ajovy
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $3.4M | 961 |
| , MD | Neurology | Santa Monica, CA | $127,349 | 14 |
| , M.D | Neurology | Las Vegas, NV | $34,560 | 5 |
| Jan Brandes | — | Nashville, TN | $26,205 | 1 |
| Jerome Goldstein | — | San Francisco, CA | $9,250 | 5 |
| , MD | Psychiatry | Lutz, FL | $3,690 | 1 |
| , MD | Neurology | Fullerton, CA | $3,026 | 1 |
| , M.D | Neurology | Redondo Beach, CA | $2,605 | 2 |
| , M.D | Family Medicine | Wichita, KS | $326.17 | 5 |
| , MD | Pulmonary Disease | North Dartmouth, MA | $156.51 | 4 |
| , M.D | Allergy & Immunology | San Diego, CA | $156.04 | 4 |
| , MD | Family Medicine | Kenosha, WI | $136.57 | 3 |
| , NP | Nurse Practitioner | Los Angeles, CA | $124.01 | 2 |
| , MD | Internal Medicine | Salt Lake City, UT | $111.00 | 2 |
| , PA-C | Physician Assistant | Las Vegas, NV | $101.31 | 6 |
| , MD | Psychiatry | Cincinnati, OH | $82.81 | 4 |
| , MD | Family Medicine | Knoxville, TN | $80.56 | 3 |
| , M.D | Psychiatry | Oceanside, CA | $76.39 | 2 |
| , FNP-BC | Family | Las Vegas, NV | $57.40 | 4 |
| , DO | Neurology | Cheshire, CT | $52.02 | 1 |
| , M.D | Anesthesiology | Los Angeles, CA | $50.76 | 2 |
| , MD | Neurology | Durham, NC | $33.98 | 2 |
| , MD | Family Medicine | Syracuse, NY | $32.17 | 2 |
| , MD | Family Medicine | East Syracuse, NY | $27.42 | 2 |
| , D.O | Student in an Organized Health Care Education/Training Program | East Syracuse, NY | $27.41 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 47
- Transactions 1,065
About Ajovy
Ajovy is a drug associated with $3.6M in payments to 47 healthcare providers, recorded across 1,065 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2023. In 2023, $610.08 was paid across 36 transactions to 28 doctors.
The most common payment nature for Ajovy is "Unspecified" ($3.6M, 99.8% of total).
Ajovy is associated with 15 research studies, including "A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE)" ($534,411).